BACKGROUND: The novel, recently described allo (antigen)-specific CD154+T cells were evaluated for their association with acute cellular rejection (ACR) in 43 adult renal transplant recipients receiving steroid-free tacrolimus after alemtuzumab induction. METHODS: Single blood samples corresponding to "for cause" allograft biopsies were assayed for CD154+naive or memory T-helper or T-cytotoxic cells in 16-hr mixed leukocyte reaction. RESULTS: Intra- and interassay variation was less than 10% for a variety of conditions. In logistic regression, leave-one-out cross-validation, and receiver-operating characteristic analyses, the rejection-risk threshold of allospecific CD154+T-cytotoxic memory cells (TcMs) associated best with biopsy-proven ACR with a sensitivity/specificity of 88% in 32 of 43 subjects. Sensitivity/specificity of 100%/88% was replicated in blinded prediction in the remaining 11 subjects. Allospecific CD154+TcM correlated inversely with CTLA4+TcM (Spearman r=-0.358, P=0.029) and increased significantly with increasing histological severity of ACR (P=2.99E-05, Kruskall-Wallis). CONCLUSIONS: The strong association between ACR and allospecific CD154+TcM may be useful in minimizing protocol biopsies among recipients at reduced rejection risk.
BACKGROUND: The novel, recently described allo (antigen)-specific CD154+T cells were evaluated for their association with acute cellular rejection (ACR) in 43 adult renal transplant recipients receiving steroid-free tacrolimus after alemtuzumab induction. METHODS: Single blood samples corresponding to "for cause" allograft biopsies were assayed for CD154+naive or memory T-helper or T-cytotoxic cells in 16-hr mixed leukocyte reaction. RESULTS: Intra- and interassay variation was less than 10% for a variety of conditions. In logistic regression, leave-one-out cross-validation, and receiver-operating characteristic analyses, the rejection-risk threshold of allospecific CD154+T-cytotoxic memory cells (TcMs) associated best with biopsy-proven ACR with a sensitivity/specificity of 88% in 32 of 43 subjects. Sensitivity/specificity of 100%/88% was replicated in blinded prediction in the remaining 11 subjects. Allospecific CD154+TcM correlated inversely with CTLA4+TcM (Spearman r=-0.358, P=0.029) and increased significantly with increasing histological severity of ACR (P=2.99E-05, Kruskall-Wallis). CONCLUSIONS: The strong association between ACR and allospecific CD154+TcM may be useful in minimizing protocol biopsies among recipients at reduced rejection risk.
Authors: Kyle A Soltys; Kentaro Setoyama; Edgar N Tafaleng; Alejandro Soto Gutiérrez; Jason Fong; Ken Fukumitsu; Taichiro Nishikawa; Masaki Nagaya; Rachel Sada; Kimberly Haberman; Roberto Gramignoli; Kenneth Dorko; Veysel Tahan; Alexandra Dreyzin; Kevin Baskin; John J Crowley; Mubina A Quader; Melvin Deutsch; Chethan Ashokkumar; Benjamin L Shneider; Robert H Squires; Sarangarajan Ranganathan; Miguel Reyes-Mugica; Steven F Dobrowolski; George Mazariegos; Rajavel Elango; Donna B Stolz; Stephen C Strom; Gerard Vockley; Jayanta Roy-Chowdhury; Marilia Cascalho; Chandan Guha; Rakesh Sindhi; Jeffrey L Platt; Ira J Fox Journal: J Hepatol Date: 2016-12-24 Impact factor: 25.083
Authors: Marjorie-Anne R Guerra; Maura Rossetti; Zhenyu Zhang; Xinkai Zhou; Emily C Whang; Robert S Venick; Elizabeth A Marcus; Suzanne V McDiarmid; Douglas G Farmer; Elaine F Reed; Laura J Wozniak Journal: Transpl Immunol Date: 2018-09-20 Impact factor: 1.708
Authors: James E Squires; Kyle A Soltys; Patrick McKiernan; Robert H Squires; Stephen C Strom; Ira J Fox; Alejandro Soto-Gutierrez Journal: Curr Transplant Rep Date: 2017-10-14
Authors: Constança Figueiredo; Dirk Wedekind; Thomas Müller; Stefanie Vahlsing; Peter A Horn; Axel Seltsam; Rainer Blasczyk Journal: Biomed Res Int Date: 2013-10-09 Impact factor: 3.411
Authors: F Boix; I Legaz; A Minhas; R Alfaro; V Jiménez-Coll; A Mrowiec; H Martínez-Banaclocha; J A Galián; C Botella; M R Moya-Quiles; F Sanchez-Bueno; R Robles; J de la Peña-Moral; P Ramirez; J A Pons; A Minguela; M Muro Journal: Clin Exp Immunol Date: 2020-10-29 Impact factor: 4.330